Replies to post #3202 on Galectin Therapeutics Inc. (GALT)

[jmh0602]

How do you interpret a fail in the study from the press release? That's a reach. Seems to me there will be a board shake up next year cause czirr's majority, and 6 of the current members will be removed. Sure would be nice to know czirrs plan. Not a lot of shareholders have been happy with trabers performance and my guess is czirr is in the same boat. Only thing that matters now: results in dec.

[Amatuer17]

The 10-k and attached letter is interesting.

I think you reached your conclusion based on this statement

"the 10X Funds insistence on putting in place an ill-advised 10B5-1 plan to sell stock prior to reporting of NASH-CX data, despite the objection of the majority of the board, underscores the deep conflict of interest between Jim's role as manager of the 10X fund and his fiduciary to the Company."

This seems to indicate the Jim wants to sell stock before the result as he is concerned that results will not be good and once stock goes down - he cannot raise money at higher price.

We can see turbulence coming up soon - such turbulence is not good for stock - so hopefully we get good results

"Jim Czirr was removed as Chair by vote of the board in January 2016. Additionally, the majority of current board members and I believe that, because of his actions and conflict of interest, he should not be a member of the board. However, the preferred share rights of the 10X Fund preclude removing him. Now, on December 14, 2017 at the annual board meeting, by virtue of the 10X Fund nominees, he will have the votes to take complete control of the board, a situation that I cannot ethically abide."

Blinded data will be unlocked on Nov 6th and then 1 month+ analysis and topline. So our timeline seems to be in place.

"I emphasize that the clinical trial data remains blinded to treatment for the patients, investigators, CRO, and company and this blind will not be broken until study data base lock which is anticipated November 6, 2017. Therefore, neither I nor anyone else in the company knows what the results of the NASH-CX trial will show.